Homburger advised Santhera on its Accelerated Bookbuilt Capital Increase
On December 12, 2018, Santhera Pharmaceuticals Holding AG (SIX: SANN), a Switzerland-based SIX Swiss Exchange-listed specialty pharmaceutical company focusing on the development and commercialization of innovative medicines for rare diseases, announced the launch of an ordinary capital increase, in which the newly created shares were offered through an accelerated bookbuilding. The offering related to 3,133,334 ordinary shares with a nominal value of CHF 1 each. The net proceeds were approximately CHF 20.1 m. The first day of trading of the new shares on SIX Swiss Exchange was December 18, 2018.
Homburger acted as counsel to Santhera. The Homburger team was led by partner Dieter Gericke (Corporate / M&A) and comprised associates Sergio Bortolani, Guy Deillon and Lorenzo Togni (all Corporate / M&A) as well as junior associate Luca Baltensperger (Corporate / M&A). Partner Stefan Oesterhelt provided tax advice.